Lifecare ASA is a Norway-based company that develops miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers. Lifecare's activities are concentrated on the development of sensor for use as a medical product, initially the sensor Sencell for continuous monitoring of glucose (blood sugar) for people with diabetes. The technology is suitable for detecting and measuring a wide range of molecules that can occur in the human body, based on variations in osmotic pressure.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
02/07/26	NOK 0.2865	-1.72%	1,124,082
01/07/26	NOK 0.2915	+0.87%	2,901,547
30/06/26	NOK 0.2890	-0.34%	2,284,848
29/06/26	NOK 0.2900	0.00%	2,586,398
26/06/26	NOK 0.2900	-1.69%	1,577,743

Real-time Oslo Bors

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Real-time Oslo Bors Other stock markets 09:36:50 02/07/2026 BST			5-day change	1st Jan Change
0.2865 ^NOK	-1.72%		-2.88%	-91.21%

06-29	Lifecare Transfers Operations from Germany to Norway, UK	MT
06-10	Lifecare Completes First Six-Month Implant Evaluation With Continued Functionality and No Adverse Biological Response	CI

Market Cap	86.9M 8.77M 7.7M 7.09M 6.6M 12.45M 834M 12.71M 85.24M 33.02M 409M 32.92M 32.21M 1.42B	P/E 2026 *	-0.77x	P/E 2027 *	-1.04x
Enterprise Value	123M 12.4M 10.89M 10.02M 9.34M 17.61M 1.18B 17.97M 121M 46.71M 579M 46.56M 45.56M 2.01B	EV / Sales 2026 *	-	EV / Sales 2027 *	25x
Free-Float	89.66%	Yield 2026 *	-	Yield 2027 *	-

06-29	Lifecare Transfers Operations from Germany to Norway, UK	MT
06-10	Lifecare Completes First Six-Month Implant Evaluation With Continued Functionality and No Adverse Biological Response	CI
05-15	Lifecare ASA, Q1 2026 Earnings Call, May 15, 2026
05-15	Lifecare ASA Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-15	Lifecare Q1 operating loss NOK 31.5 mln	RE
04-23	Lifecare ASA Approves Board Appointments	CI
03-26	Lifecare ASA Announces Operational Restructuring And Centralization Of Operations	CI
03-26	Lifecare ASA Announces Discontinuation of the Business Operations of Lifecare Germany GmbH	CI
03-26	Lifecare ASA to Close German Operations, Consolidate Activities Under Planned Centralization	MT
03-16	Lifecare Chief Scientific Officer to Step Down	MT
03-13	Andreas Pfützner to Step Down as Chief Scientific Officer of Lifecare ASA	CI
03-10	Lifecare receives regulatory feedback on first-in-human application	RE
03-10	Lifecare ASA Receives Regulatory Feedback on First-in-Human Application	CI

06:03am	LIFE: Update on production transfer and longevity programme	AQ
06-26	LIFE: Operational update regarding Lifecare Germany GmbH (i.L)	PU
06-22	LIFE: Independent tissue analysis confirms no adverse tissue response after six months of implantation	AQ
06-12	Lifecare ASA: Final results following expiry of exercise period for Warrants Series 2 issued in connection with Rights Issue	PU
06-10	Lifecare ASA: Mandatory notification of trade	PU

Lifecare ASA Share Price

Stocks

LIFE

NO0013355859

Biotechnology & Medical Research

Valuation: Lifecare ASA

Chart: Lifecare ASA

Latest news : Lifecare ASA

Last Transcript: Lifecare ASA

Analysts' recommendations: Lifecare ASA

Press Releases: Lifecare ASA

News in other languages: Lifecare ASA

Quotes and Performance

Course Extremes

Managers and Directors: Lifecare ASA

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	-1.72%
1 week	-2.88%
Current month	-0.87%
1 month	-1.21%
3 months	-32.27%
6 months	-83.58%
Current year	-91.21%

1 week	0.28	0.32
1 month	0.27	0.42
Current year	0.27	2
1 year	0.27	23.5
3 years	0.27	82.16
5 years	0.27	82.16
10 years	0.27	117

Manager	Title	Age	Since
Joacim Holter CEO	Chief Executive Officer	50	06/09/2020
Petter Nielsen DFI	Director of Finance/CFO	-	31/03/2026
Torsten Ernst PRN	Corporate Officer/Principal	-	29/02/2024

Director	Title	Age	Since
Trine Teigland BRD	Director/Board Member	-	25/06/2020
Morten Foros Krohnstad CHM	Chairman	-	07/05/2021
Lutz Heinemann BRD	Director/Board Member	-	19/11/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LIFECARE ASA	-1.72%	-2.88%	-94.85%	-98.90%	8.77M
LONZA GROUP AG	+0.20%	+4.99%	+0.93%	+6.54%	48.62B
REVOLUTION MEDICINES, INC.	+0.12%	+10.45%	+408.29%	+600.97%	39.86B
IQVIA HOLDINGS INC.	+5.17%	+9.47%	+24.96%	-9.60%	33.91B
BEONE MEDICINES AG	+2.02%	+4.91%	+18.59%	+63.06%	32.32B
CELLTRION, INC.	+0.69%	+1.04%	+14.23%	+30.86%	24.73B
ASCENDIS PHARMA A/S	+0.40%	+12.51%	-	-	16.63B
MEDPACE HOLDINGS, INC.	+2.64%	+6.00%	+69.30%	+126.33%	15.52B
EUROFINS SCIENTIFIC SE	+0.67%	+0.94%	+13.62%	+18.34%	13.63B
ICON PUBLIC LIMITED COMPANY	+0.77%	+10.67%	+17.58%	-30.04%	13.41B
Average	+1.10%	+5.90%	+52.52%	+78.62%	23.87B
Weighted average by Cap.	+1.43%	+7.14%	+88.36%	+128.63%

	2026 *	2027 *
Net sales	-	5M 505K 443K 408K 380K 717K 47.97M 731K 4.9M 1.9M 23.55M 1.89M 1.85M 81.94M
Net income	-86M -8.68M -7.62M -7.01M -6.54M -12.32M -825M -12.58M -84.35M -32.68M -405M -32.58M -31.88M -1.41B	-82M -8.27M -7.26M -6.69M -6.23M -11.75M -787M -11.99M -80.43M -31.16M -386M -31.07M -30.4M -1.34B
Net Debt	36M 3.63M 3.19M 2.94M 2.74M 5.16M 345M 5.26M 35.31M 13.68M 170M 13.64M 13.34M 590M	38M 3.83M 3.37M 3.1M 2.89M 5.45M 365M 5.56M 37.27M 14.44M 179M 14.4M 14.09M 623M